AZN AstraZeneca
- 76.770
- +0.690+0.91%
- 77.170
- +0.400+0.52%
AstraZeneca News
Positive Outlook for Cellectis SA With Strategic AstraZeneca Partnership and Promising Clinical Developments
The next domestically produced blockbuster that straddles two major diseases
Looking at the global R&D landscape, AKT inhibitor development is a promising and uncrowded blue ocean racetrack. Currently, only AstraZeneca's Capivasertib has been approved for marketing, while LAE002 (Afuresertib) of Laikai Pharmaceuticals (02105) is ranked second in the world.
AstraZeneca Is Maintained at Buy by Argus Research
AstraZeneca Is Maintained at Buy by Argus Research
Argus Research Maintains Buy on AstraZeneca, Raises Price Target to $85
Argus Research analyst Jasper Hellweg maintains AstraZeneca with a Buy and raises the price target from $80 to $85.
Third Human Bird Flu Case Found in U.S.
AstraZeneca, Novo Nordisk, Novartis Show Innovation Momentum -- Market Talk
1551 GMT - AstraZeneca, Novo Nordisk and Novartis are charting strong innovation narrative that should boost near and mid-term earnings momentum, Goldman Sachs analysts say in a note. AstraZeneca's in
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
Association of Cancer Care Centers Announces Virtual Roadmap to Support EHR Integration for Biomarker Testing
WASHINGTON, May 30, 2024 /PRNewswire/ -- The Association of Cancer Care Centers (ACCC) and LUNGevity today announced the launch of the Electronic Health Records (EHR) Integrations for Biomarker Testi
Goldman Sachs pushes European pharmaceutical stocks: innovation leads the future, and the three giants receive buying ratings
The European pharmaceutical company focused on developing new drug combinations was recognized by Goldman Sachs Group analysts.
AstraZeneca Target Started at GBP152 by Goldman Sachs
AstraZeneca Target Started at GBP152 by Goldman Sachs
Compugen Earns Milestone From AstraZeneca Trial
Goldman Sachs Kicks Off AstraZeneca Coverage at Buy
Goldman Sachs on Thursday initiated its coverage of drugmaker AstraZeneca (AZN.L, AZN.ST) with a buy rating and a price target of 152.00 pounds sterling. Price (GBP): £12018.00, Change: £+88.00, Perce
CinRx Pharma Announces Additional $73 Million Financing
Financing brings total funds raised to $176M to advance diverse portfolio of high-impact medicines and expand efforts to additional high unmet needsCurrent portfolio of CinCos include two clinical-sta
European pharmaceutical giant praised by Goldman Sachs: innovation is king, and three shares received a “buy” rating
European pharmaceutical companies focused on building new drug combinations were recognized by Goldman Sachs analysts.
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Goldman Sachs Initiates Coverage On AstraZeneca With Buy Rating, Announces Price Target of $97
Goldman Sachs analyst Rajan Sharma initiates coverage on AstraZeneca (NASDAQ:AZN) with a Buy rating and announces Price Target of $97.
AstraZeneca Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 26.48% Goldman Sachs → $97 Initiates Coverage On → Buy 04/26/2024 6.92% BMO Capital $80 → $82 M
AstraZeneca Started at Buy at Goldman, Which Rates GSK a Neutral
By Steve Goldstein Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral. Analysts led by Rajan Sharma said AstraZeneca is its preferred name in
Express News | Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
ConcertAI: ASCO 2024 Study Uses ConcertAI Oncology Dataset to Find Earlier Treatment With Oliparib Monotherapy May Improve Duration of Therapy and Overall Survival
CAMBRIDGE, Mass., May 29, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology predictive and generative AI SaaS and Real-World Data (RWD) Solutions for clinical research, announced the results of
Analysis
Price Target
No Data
